Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3

Bart Barlogie, Elias Anaissie, Frits Van Rhee, Jeffrey Haessler, Klaus Hollmig, Mauricio Pineda-Roman, Michele Cottler-Fox, Abid Mohiuddin, Yazan Alsayed, Guido Tricot, Vanessa Bolejack, Maurizio Zangari, Joshua Epstein, Nathan Petty, Douglas Steward, Bonnie Jenkins, Jennifer Gurley, Ellen Sullivan, John Crowley, John D. Shaughnessy

Research output: Contribution to journalArticle

239 Scopus citations

Abstract

Total therapy 3 incorporated bortezomib into a melphalan-based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-d continuous infusions of cis-platin, doxorubicin, cyclophosphamide, etoposide); 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%). A minimum of 20 × 106 CD34 cells/kg was collected in 87% of patients; 83% completed both transplants, and only 5% suffered a treatment-related death. At 24 months, 83% had achieved near-complete remission, which was sustained in 88% at 2 years from its onset. With a median follow-up of 20 months, 2-year estimates of event-free and overall survival were 84% and 86% respectively. The 44 patients who experienced an event more often had a high-risk gene array profile, cytogenetic abnormalities and indicators of high lactate dehydrogenase, beta-2-microglobulin, creatinine and International Staging System stage. Toxicities of grade > 2 included thrombo-embolic events in 27% and peripheral neuropathy in 12%. Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients.

Original languageEnglish (US)
Pages (from-to)176-185
Number of pages10
JournalBritish Journal of Haematology
Volume138
Issue number2
DOIs
StatePublished - Jul 1 2007

Keywords

  • Autotransplant
  • Bortezomib
  • Myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3'. Together they form a unique fingerprint.

  • Cite this

    Barlogie, B., Anaissie, E., Van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J., & Shaughnessy, J. D. (2007). Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. British Journal of Haematology, 138(2), 176-185. https://doi.org/10.1111/j.1365-2141.2007.06639.x